The legal action, spearheaded by the firm Hagens Berman, targets management’s public assurances that the iLet device required minimal user engagement and was seeing widespread clinical success. While leadership dismissed a 2025 FDA Form 483 inspection as a routine issue regarding complaint definitions, the subsequent February 2026 FDA warning letter painted a starkly different picture. Regulatory findings indicated that Beta Bionics failed to adequately analyze quality data or report device malfunctions that resulted in serious adverse health outcomes.
In section Releases
Beta Bionics Faces Class Action Over Alleged iLet Safety Concealment
Investors who purchased Beta Bionics stock between July 30, 2025, and February 24, 2026, are now seeking damages in a federal securities class action. The lawsuit follows revelations that the company allegedly downplayed FDA compliance warnings while concealing thousands of safety complaints regarding its iLet insulin delivery system.
The complaint alleges the company prioritized revenue over patient safety by withholding information about life-threatening hypoglycemic events. Hagens Berman partner Reed Kathrein stated the firm is investigating whether these omissions intentionally misled shareholders. With a lead plaintiff deadline set for November 3, 2026, the firm is also soliciting input from whistleblowers who may hold non-public details regarding the company's internal reporting practices.
Comments (0)
No comments yet. Be the first!